ScreenerHero

ACXPAcurx Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · acurxpharma.com
1.470USD+2.08%Mkt Cap: 6.32M $P/E: —

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.32M $
Enterprise Value-3.02M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-7.97M $
Revenue/Share—
Last Price1.470 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00510M1045
Valuation
P/E (Trailing)—
P/E (Forward)-0.83
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.83
EPS (TTM)-2.46
EPS (Forward)-1.75
52W Range
1.3102% of range8.340
52W High8.340 USD
52W Low1.310 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-151.21%
ROA-103.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.79M $
CapEx (TTM)—
FCF Margin—
FCF Yield-63.07%
Net Debt-10.66M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio3.88
Quick Ratio3.80
Book Value/Sh1.741 USD
Cash/Share2.022 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateAug 5, 2025
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.00 USD
Upside (mean)+1056.5%
Target Range10.00 USD – 31.00 USD
$10.00+1056.5% to mean$31.00
# Analysts3
Ownership
Shares Out.4.30M
Float5.11M
Insiders2.44%
Institutions3.94%
Short Interest
Short Ratio1.4d
Short % Float3.07%
Short % Out.2.98%
Shares Short127.92K
Short (prev mo.)135.52K
Technical
SMA 501.508 (-2.5%)
SMA 2002.597 (-43.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)156.96K
Avg Vol (10d)311.72K
Technical Indicators
RSI (14)47.8
MACD-0.0228
MACD Signal-0.0356
MACD Hist.+0.0127
BB Upper1.586 USD
BB Middle1.465 USD
BB Lower1.343 USD
BB Width16.62%
ATR (14)0.1476 USD
Vol Ratio (20d)0.46x